Indian Generics File Fewer Patent Challenges In New Era
This article was originally published in PharmAsia News
Executive Summary
Indian drug makers are backing away from their tendency to challenge the patents of branded drugs in favor of taking a more cautious approach. As a result, the number of patent challenges filed in the United States by Indian pharmas in the past few years has declined by nearly half. The trend has been slowed in part because the owners of those patents have been taking steps to compete with the generics makers for specific drugs. As a result, Dr. Reddy's, Glenmark, Ranbaxy, Sun Pharma and Wockhardt are becoming more selective in their challenges. (Click here for more